Foundayo Logs Only 3,707 Second-Week Scripts While Shares Fall 4%
Eli Lilly’s Foundayo recorded only 3,707 U.S. prescriptions in its second week, significantly trailing Novo Nordisk’s 18,410 Wegovy pill scripts in its equivalent launch period. Zepbound prescriptions also dipped 2% week-over-week, prompting a nearly 4% decline in Eli Lilly shares on Friday.
1. Early Prescription Data
Foundayo recorded 3,707 U.S. prescriptions in its second week, up from 1,390 in its debut two-day period, indicating a slower rollout compared to competitor drugs. Zepbound injections also fell roughly 2% week-over-week during the tracked period.
2. Market Comparison
Novo Nordisk’s oral Wegovy achieved 18,410 scripts in its second week, nearly five times Foundayo’s tally, underlining the market’s strong initial appetite for Wegovy. The gap highlights challenges for oral obesity treatments against established brands.
3. Stock Reaction
Eli Lilly shares declined nearly 4% on April 24 as investors reacted to the slower-than-expected uptake of its obesity therapies. Market participants cited early data as a potential drag on the company’s key growth drivers.
4. Analyst Commentary
Analysts caution that one week of prescription data may not reflect long-term trends but acknowledge that obesity drugs remain a core pillar of future revenue. Investors will monitor upcoming weekly reports for signs of acceleration or persistent underperformance.